Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenvatinib plus hepatic intra-arterial cisplatin in advanced hepatocellular carcinoma after or unsuitable for immune checkpoint inhibitors
jRCT1041210163Phase 2Active, not recruiting
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC). Primary endpoint: Objective response rate (RECIST). Started Mar 2022; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1041210163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041210163.